KindlyMD (NAKA) Stock Price, News & Analysis

Company Overview

Kindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.

Key Stats

• Today's Range: $4.08 to $4.33
• 50-Day Range: $4.08 to $10.56
• 52-Week Range: $4.05 to $679.20
• Volume: 169,261 shs
• Average Volume: 466,451 shs
• Market Capitalization: $73.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Hold

KindlyMD Stock Analysis - MarketRank™

KindlyMD scored higher than 81% of companies evaluated by MarketBeat, and ranked 114th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

KindlyMD has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

KindlyMD has a consensus price target of $30.00, representing about 612.6% upside from its current price of $4.21.

Amount of Analyst Coverage

KindlyMD has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for KindlyMD are expected to grow in the coming year, from ($16.80) to ($1.72) per share.

Price to Book Value per Share Ratio

KindlyMD has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.50% of the float of KindlyMD has been sold short.

Short Interest Ratio / Days to Cover

KindlyMD has a short interest ratio ("days to cover") of 1.75, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in KindlyMD has recently decreased by 96.80%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

KindlyMD does not currently pay a dividend.

Dividend Growth

KindlyMD does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

6 people have searched for NAKA on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.

MarketBeat Follows

4 people have added KindlyMD to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $992,908.00 in company stock, which represents 1.3554% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, KindlyMD insiders have bought more of their company's stock than they have sold. Specifically, they have bought $992,908.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

24.49% of the stock of KindlyMD is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

KindlyMD has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 6/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:NAKA
• Previous Symbol: NASDAQ:NAKA
• CIK: 1946573
• Web: N/A
• Phone: (385) 388-8220
• Fax: N/A
• Employees: N/A
• Year Founded: 2019

Price Target and Rating

• Average Price Target for KindlyMD: $30.00
• High Price Target: $40.00
• Low Price Target: $20.00
• Potential Upside/Downside: +612.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($43.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$52.23 million
• Net Margins: -7,397.12%
• Pretax Margin: -7,397.12%
• Return on Equity: -81.32%
• Return on Assets: -54.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.25
• Quick Ratio: 0.25

Sales & Book Value

• Annual Sales: $1.82 million
• Price / Sales: 40.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $46.97 per share
• Price / Book: 0.09

Miscellaneous

• Outstanding Shares: 17,400,000
• Free Float: 13,140,000
• Market Cap: $73.25 million
• Optionable: N/A
• Beta: 15.84